Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
J-1149
- Development stage
- Preclinical
- Lead developer
- Yanbian University
- Modality
- Small Molecules
01
Overview
J-1149: sourced facts only. name: "J-1149 (compound 15g) administered orally at a dose of 15 mg/kg demonstrates favorable pharmacokinetic (PK) properties" [1] name: "the imidazole derivative J-1149, which exhibited inhibitory activity against ALK5," [2] target: "the imidazole derivative J-1149, which exhibited inhibitory activity against ALK5," [2] developer: "Key Laboratory of Traditional Chinese Korean Medicine Research (Yanbian University) of State Ethnic Affairs Commission," [2] stage: "Our findings suggested that J-1149 significantly attenuated HSC activation and liver fibrogenesis by acting on the TGF-β/Smad signaling pathway." [2] modality: "the imidazole derivative J-1149, which exhibited inhibitory activity against ALK5," [2]
02
Targets
TGFBR1
Beyond the preview
Go deeper on J-1149.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on J-1149.